Oxidopamine (hydrobromide)

• Description:

  Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome[1][2][3][4].

• Product Name Alternative:

  6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; Caspase; COX; Dopamine Receptor; Interleukin Related; Mitophagy; p38 MAPK; PGE synthase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Oxidopamine-hydrobromide.html

• Purity:

  99.65

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic)

• Smiles:

  OC1=CC(CCN)=C(O)C=C1O.[H]Br

• Molecular Formula:

  C8H12BrNO3

• Molecular Weight:

  250.09

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Fujita H et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of the Akt pathway. Brain Res. 2006 Oct 3;1113 (1) :10-23.|[2]Soto-Otero R et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000 Apr;74 (4) :1605-12.|[3]Jin F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur J Pharmacol. 2008 Dec 14;600 (1-3) :78-82. |[4]Kang X, et al. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Sci Rep. 2017 Aug 25;7 (1) :9459.|[5]Jin F, et al. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats[J]. European journal of pharmacology, 2008, 600 (1-3) : 78-82.|[6]Lee C S, et al. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat[J]. Neuroscience, 1996, 72 (3) : 641-653.|[7]Ryan RE, et al. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br J Pharmacol. 2001 Apr;132 (8) :1650-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Caspase 3; Caspase 8; Caspase 9; COX-2; IL-1

• Citation 01:

  Am J Chin Med. 2025;53 (3) :863-888.|Am J Physiol Cell Physiol. 2025 Jun 1;328 (6) :C1699-C1715.|Biochem Biophys Res Commun. 2025 Sep 30:782:152582.|Cell Host Microbe. 2024 Dec 12:S1931-3128 (24) 00444-X.|Cell Stem Cell. 2023 Jun 1;30 (6) :832-850.e6.|CNS Neurosci Ther. 2024 Feb;30 (2) :e14407.|Invest Ophthalmol Vis Sci. 2025 Jun 2;66 (6) :13.|J Immunother Cancer. 2024 Dec 9;12 (12) :e009910.|J Transl Med. 2025 Jan 23;23 (1) :112.|Mol Biol Rep. 2023 Jan;50 (1) :331-338.|Nat Commun. 2024 Nov 28;15 (1) :10361.|Neurol Res. 2018 Sep;40 (9) :736-743.|NPJ Parkinsons Dis. 2025 Nov 28;11 (1) :342.|Res Sq. 2025 Apr 27.|Res Sq. 2025 Jun 12.|Stem Cells Int. 2024 Sep 3:2024:2792909.|Behav Brain Res. 2024 Mar 28:462:114871.|Biomed Rep. 2025 Feb 25;22 (4) :74.|Brain Res. 2023 Jun 1:1808:148320.|Cell Metab. 2022 Dec 6;34 (12) :1999-2017.e10.|Chem Biodivers. 2024 Jun;21 (6) :e202301509.|Chinese Pharmacological Bulletin. 2018 May; 34 (5) : 620-626.|CNS Neurosci Ther. 2023 Oct;29 (10) :2925-2939.|Free Radic Biol Med. 2025 Jan:226:84-95.|Funct Integr Genomics. 2024 Sep 17;24 (5) :161.|Gene Ther. 2024 Nov;31 (11-12) :614-624.|Immunity. 2024 Feb 13;57 (2) :364-378.e9.|Ind Crops Prod. 2025 Nov 19;238:122328.|Int J Mol Sci. 2025 Mar 19;26 (6) :2762.|Metab Brain Dis. 2021 Apr;36 (4) :609-625.|Metabolism. 2025 Apr 7:156262.|Molecules. 2024 Oct 31;29 (21) :5160.|Oxid Med Cell Longev. 2022 Aug 8:2022:5392966.|Research Square Preprint. 2023 Jun 28.|Research Square Print. 2022 Jul.

• CAS Number:

  [636-00-0]